Final overall survival (OS) results from the INAVO120 trial (NCT04191499) confirmed that the addition of inavolisib (Itovebi) ...

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced multiple clinical research results to be presented at the 2025 American Society of Clinical ...

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is scheduled to take place in Chicago, Illinois, USA from May 30 to June 3. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990 ...

Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

Still, the therapies’ modest benefit as a maintenance therapy points to how better treatments are needed for small cell lung ...

Preliminary results from a different ongoing study suggest that the VeriStrat test may have similar indications in patients with other types of solid tumors. Data from this study is expected to be ...

David P. Carbone, MD, PhD, discusses the outcomes of the phase 3 CheckMate 9LA trial in non–small cell lung cancer based on treatment discontinuation.

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin ...

Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. | ...

ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage ...